PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277789
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - The Prognostic Role of Cancer Stem Cell Markers for Long-term Outcome After
      Resection of Colonic Liver Metastases.
PG  - 313-320
AB  - BACKGROUND/AIM: To assess the expression of cancer stem cell (CSC) markers CD44, 
      CD133 and CD24 in colon cancer liver metastases and analyse their predictive
      value for overall survival (OS) and disease-free survival (DFS) after liver
      resection. MATERIALS AND METHODS: Patients operated on for colon cancer liver
      metastases were included. CSC marker expression was determined through
      immunohistochemistry analysis. OS and DFS were compared between marker-positive
      and marker-negative patients. Multivariate analysis was performed to select
      predictive variables for OS and DFS. RESULTS: CD133-positive patients had a worse
      DFS than CD133-negative patients, with a median DFS of 12 and 25 months
      (p=0.051). Multivariate analysis selected CD133 expression as a significant
      predictor for DFS. CD44 and CD24 were not found to predict OS or DFS. CONCLUSION:
      CD133 expression in colonic liver metastases is a negative prognostic factor for 
      DFS after liver resection. In the future, CD133 could be used as a biomarker for 
      risk stratification, and possibly for developing novel targeted therapy.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Spelt, Lidewij
AU  - Spelt L
AD  - Department of Surgery, Clinical Sciences Lund, Lund University and Skane
      University Hospital, Lund, Sweden [email protected]
FAU - Sasor, Agata
AU  - Sasor A
AD  - Department of Pathology, Skane University Hospital, Lund, Sweden.
FAU - Ansari, Daniel
AU  - Ansari D
AD  - Department of Surgery, Clinical Sciences Lund, Lund University and Skane
      University Hospital, Lund, Sweden.
FAU - Hilmersson, Katarzyna Said
AU  - Hilmersson KS
AD  - Department of Pathology, Skane University Hospital, Lund, Sweden.
FAU - Andersson, Roland
AU  - Andersson R
AD  - Department of Surgery, Clinical Sciences Lund, Lund University and Skane
      University Hospital, Lund, Sweden.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (AC133 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD24 Antigen)
RN  - 0 (CD24 protein, human)
RN  - 0 (CD44 protein, human)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (PROM1 protein, human)
SB  - IM
MH  - AC133 Antigen/*metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor
MH  - CD24 Antigen/*metabolism
MH  - Colon/pathology
MH  - Colonic Neoplasms/*pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Hepatectomy
MH  - Humans
MH  - Hyaluronan Receptors/*metabolism
MH  - Liver/pathology/surgery
MH  - Liver Neoplasms/mortality/*secondary/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplastic Stem Cells/*metabolism
OTO - NOTNLM
OT  - *Colonic neoplasms
OT  - *disease-free survival
OT  - *liver resection
OT  - *metastasis
OT  - *neoplastic stem cells
OT  - *survival analysis
EDAT- 2017/12/27 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/09/28 00:00 [received]
PHST- 2017/10/12 00:00 [revised]
PHST- 2017/10/13 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 38/1/313 [pii]
AID - 10.21873/anticanres.12224 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):313-320. doi: 10.21873/anticanres.12224.